Short-Term Debt to Capital: Genetic Technologies (GENE)

Genetic Technologies (GENE) develops innovative early detection systems for oncology and cardiac pathologies, leveraging patent-protected AI algorithms. Business growth is driven by expansion into western regions and the promotion of a personalized treatment approach via GeneType tests. However, the company's liquidity stands at 0.46, necessitating strict cost control. This chart illustrates the price action of the short-term debt-to-equity ratio.

This indicator measures the business's dependence on short-term liabilities relative to equity, where a declining ratio signals deleveraging and strengthened financial stability. By analyzing the trend of loans with a maturity of up to one year relative to equity, an investor can assess the ability of Genetic Technologies (GENE) to finance the expansion of GeneType tests in Western markets without excessive debt load.